# DeepSeek Response

**Model:** `deepseek-reasoner`  
**Prompt:** `analysis_prompt.md`  
**Generated:** 2026-05-21 22:04:26

---

## Integrated Mechanistic Explanation

The mutual exclusivity between *TP53* and the five genes—*ATM*, *POLD1*, *TRRAP*, *SOX9*, and *CDH1*—in gastric cancer (GC) arises from a combination of **functional redundancy** (alternative disruption of the p53 pathway) and **tumor subtype separation** (distinct molecular classes that are inherently *TP53*‑wild‑type). The absence of a single shared pathway across all five genes strongly indicates that they mark **different *TP53*‑wild‑type subgroups** rather than a unified mechanism. Below, each gene is analysed with respect to the data and known GC subtypes (TCGA: EBV, MSI, GS, CIN; ACRG: MSI, MSS/EMT, MSS/TP53+, MSS/TP53−).

### 1. *ATM* – Redundancy via the ATM→p53 Axis

**Mechanism:** ATM directly phosphorylates TP53 at Ser‑15 upon DNA double‑strand breaks, stabilising p53 and activating its transcriptional program. Loss‑of‑function mutations in ATM abrogate this upstream activation, rendering wild‑type p53 ineffective in the DNA‑damage response. Thus, *ATM* mutation is **functionally equivalent** to *TP53* loss: both cripple the p53‑dependent checkpoint. A tumour that already inactivates ATM gains no additional selective advantage from also mutating *TP53*; conversely, a *TP53*‑mutant tumour does not require ATM inactivation. This redundancy explains the mutual exclusivity (OR = 0.26, p = 5.4×10⁻⁴).

**Subtype Context:** In TCGA, ATM mutations are enriched in the **MSI** subtype (microsatellite instability, often *TP53*‑wild‑type) and occasionally in the **GS** subtype, but are rare in the CIN subtype (which is *TP53*‑mutant). Both MSI and GS are known to have low *TP53* mutation rates. The BioGRID data confirm that ATM directly phosphorylates TP53 and shares hubs like BRCA1, MDC1, and RPA with the p53 network, further supporting a functional bypass.

### 2. *POLD1* – Distinct Hypermutator Subtype

**Mechanism:** Proofreading‑domain mutations in *POLD1* (and *POLE*) create an **ultramutator phenotype** with massive numbers of base‑substitution mutations. These tumours achieve oncogenic transformation through **high mutational load** that easily hits multiple driver genes (e.g., *KRAS*, *PIK3CA*), bypassing the need for p53 loss. Additionally, the extreme replicative stress in these cells may require an intact p53 pathway to prevent mitotic catastrophe, making *TP53* loss counterselected. The low OR (0.23, p = 3.8×10⁻³) reflects strong subtype separation.

**Subtype Context:** TCGA identifies a small **hypermutated** cluster (often *POLE/POLD1*‑mutant) that is distinct from CIN and GS. This group is characterised by a very high mutation burden, microsatellite stability (or low MSI), and **wild‑type *TP53***. In ACRG, a similar group falls under **MSI** or a separate hypermutator subset. The interaction data show *POLD1* shares hubs like PCNA, RPA, and BRCA1 with ATM, indicating a DNA‑repair axis, but the mutual exclusivity is driven by alternate oncogenic routes rather than direct functional equivalence.

### 3. *TRRAP* – Functional Equivalence in p53 Transcriptional Output

**Mechanism:** TRRAP is an essential component of the NuA4/TIP60 histone acetyltransferase (HAT) complex and is **required for p53‑dependent transcriptional activation**. Even if p53 protein is present and stabilised, it cannot properly transactivate target genes (e.g., *CDKN1A*, *BAX*) without TRRAP‑dependent chromatin acetylation. Therefore, *TRRAP* loss‑of‑function mutations achieve the same downstream effect as *TP53* loss—failure of the p53 transcriptional program. Mutual exclusivity (OR = 0.31, p = 6.0×10⁻³) arises because co‑mutation is redundant.

**Subtype Context:** *TRRAP* mutations are rare in GC and have not been firmly assigned to a specific subtype. However, TRRAP also interacts with β‑catenin and TCF/LEF (Wnt pathway), and its loss could affect Wnt signalling, which is aberrant in **GS** (diffuse) tumours. Given the lack of overlap with DNA‑repair hubs, *TRRAP*‑mutant tumours likely fall into a **MSS/EMT** or **GS‑like** group that is *TP53*‑wild‑type. The data show that TRRAP is a BioGRID hub connecting to TP53 directly (40 evidence rows) and also to EP300 and MYC, supporting a transcriptional‑coactivator role that substitutes for p53 loss.

### 4. *SOX9* – Intestinal Stem Cell Identity in GS/Metaplasia

**Mechanism:** SOX9 is a master transcription factor for intestinal stem cell maintenance and is expressed in gastric **intestinal metaplasia**, a precursor of intestinal‑type GC. SOX9 mutations (likely loss‑of‑function in this context) disrupt the intestinal differentiation programme and promote a more **diffuse or stem‑cell‑like phenotype**. This pathway is independent of p53; SOX9 loss activates alternative oncogenic cascades (e.g., uncontrolled Wnt/β‑catenin signalling) that make *TP53* mutation unnecessary. The extremely low OR (0.11, p = 3.2×10⁻⁵) indicates near‑complete separation.

**Subtype Context:** SOX9 is a well‑known marker of the **ACRG MSS/EMT** subtype (mesenchymal, diffuse‑type, *TP53*‑wild‑type) and also aligns with the **TCGA GS** subtype. GS tumours are characterised by *CDH1*, *RHOA* mutations, and **wild‑type *TP53***. In contrast, intestinal‑type CIN tumours (TP53‑mutant) typically lose SOX9 expression. Thus, *SOX9* mutual exclusivity is a classic example of **subtype separation**: GS versus CIN.

### 5. *CDH1* – Archetypal Subtype Separation with GS

**Mechanism:** CDH1 (E‑cadherin) loss is the defining event of **diffuse‑type** gastric cancer (both hereditary and sporadic). CDH1 inactivation drives epithelial‑to‑mesenchymal transition (EMT), leading to invasion and metastasis without requiring p53 loss. The mutual exclusivity (OR = 0.42, p = 9.8×10⁻³) is the strongest literature‑supported case of subtype separation: *CDH1*‑mutant tumours are nearly always **TP53‑wild‑type**, whereas *TP53*‑mutant tumours are almost exclusively intestinal‑type (CIN or MSI). Note that 18 co‑mutations exist (6.6% of the 272 double‑mutant samples), likely representing rare cases of mixed histology or convergent evolution, but the overall trend is clear.

**Subtype Context:** In TCGA, **GS** (genomically stable) is defined by *CDH1* or *RHOA* mutations and is **TP53‑wild‑type**. The ACRG **MSS/EMT** subtype is essentially equivalent. Conversely, **CIN** carries *TP53* mutations in >70% of cases. Thus, CDH1 and TP53 define two mutually exclusive molecular lineages.

## Synthesis: Not One Subgroup, but Multiple

The absence of any shared pathway or GO term across all five genes, and the diversity of their biological roles, confirms that they do **not** converge on a single *TP53*‑wild‑type subgroup. Instead, they partition into at least three distinct classes:

| Gene | Mechanism | Predominant TP53‑wild‑type Subtype(s) |
|------|-----------|----------------------------------------|
| **ATM** | Functional redundancy via p53 phosphorylation | MSI (TCGA), occasionally GS |
| **POLD1** | Hypermutator subtype bypasses p53 loss | Hypermutated (TCGA) / MSI (ACRG) |
| **TRRAP** | Functional equivalence in p53 transcriptional output | Likely GS / MSS/EMT (rare) |
| **SOX9** | Intestinal stem‑cell identity; GS differentiation | GS (TCGA) / MSS/EMT (ACRG) |
| **CDH1** | Diffuse‑type (EMT) lineage | GS (TCGA) / MSS/EMT (ACRG) |

Thus, the mutual exclusivity pattern of *TP53* is driven by the co‑existence of **multiple fundamentally different oncogenic routes** in gastric cancer, each of which either renders p53 loss redundant or defines a tumour subtype where *TP53* is already wild‑type by virtue of its distinct aetiology. The data provide no evidence for negative epistasis (synthetic lethality), given that a small number of co‑mutations are observed, and the odds ratios, while significant, are not zero. Instead, the pattern reflects strong **evolutionary canalisation** along subtype‑specific trajectories.